# US 2009/0269368 A1 · Pseudomonas exotoxin a-like chimeric immunogens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0269368 A1
- Document ID: US20090269368A1
- Status: Published application
- Kind: A1
- Application number: 11/962,007
- Filed: 2007-12-20
- Published: 2009-10-29
- Earliest claimed: 1997-07-11
- Assignees: The Gov. of the USA as Represented by the Secretary of the Dept.of Health & human Services
- Inventors: David J. FitzGerald
- Web page: https://patentgrep.com/patent/US20090269368A1

## CPC

- C07K 14/005: from viruses
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/21: from Pseudomonadaceae (F)
- C07K 16/1145: {Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/51: {comprising whole cells, viruses or DNA/RNA}
- C07K 2319/00: Fusion polypeptide
- C12N 2740/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This invention provides Pseudomonas exotoxin A-like chimeric immunogens that include a non-native epitope in the Ib domain of Pseudomonas exotoxin. Methods of eliciting an immune response using these immunogens also are provided.

## Claims

### Claim 1

A non-toxic Pseudomonas exotoxin A-like (“PE-like”) chimeric immunogen comprising: (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a translocation domain comprising an amino acid sequence substantially identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol; and (3) a non-native epitope domain comprising an amino acid sequence of between 5 and 1500 amino acids that encodes a non-native epitope.

### Claim 2 (depends on 1)

The immunogen of claim 1 having the amino acid sequence of PE (SEQ ID NO:2) except that the sequence of domain Ib comprises the non-native epitope between two cysteine residues of domain Ib.

### Claim 3 (depends on 1)

The immunogen of claim 1 wherein the cell recognition domain is domain Ia of PE.

### Claim 4 (depends on 1)

The immunogen of claim 1 wherein cell recognition domain binds to α2-macroglobulin receptor (“α2-MR”), epidermal growth factor (“EGF”) receptor; the IL-2 receptor; the IL-6 receptor; HIV-infected cells; a chemokine receptor; a leukocyte cell surface receptor; a ligand for the IgA receptor; or an antibody or antibody fragment directed to a receptor.

### Claim 5 (depends on 1)

The immunogen of claim 1 wherein cell recognition domain comprises amino acid sequences of a growth factor or an antibody.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The immunogen of claim 1 wherein the translocation domain comprises amino acids 280 to 364 of domain II of PE.

### Claim 8 (depends on 1)

The immunogen of claim 1 wherein the translocation domain is domain II of PE.

### Claim 9 (depends on 1)

The immunogen of claim 1 wherein the non-native epitope domain comprises a cysteine-cysteine loop that comprises the non-native epitope.

### Claim 10 (depends on 1)

The immunogen of claim 1 wherein the non-native epitope domain comprises an amino acid sequence encoding a non-native epitope inserted between two cysteine residues of domain Ib of PE.

### Claim 11 (depends on 1)

The immunogen of claim 1 wherein the non-native epitope domain comprises an amino acid sequence selected from CTRPNYNKRK RIHIGPGRAF YTTKNIIGTI RQAHC (SEQ ID NO:3) or CTRPSNNTRT SITIGPGQVF YRTGDIIGDI RKAYC (SEQ ID NO:4).

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The immunogen of claim 1 which has an amino acid sequence selected from:
PE (SEQ ID NO:2) except that amino acids 361-384 are substituted with the amino acid sequence: Gly Ala Ala Asn Leu His Cys Gly Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Lys Cys Met Gln Gly Pro Ala Asp (SEQ ID NO:7) and amino acid Glu at position 553 is deleted (ntPE-V3MN14), and
PE (SEQ ID NO:2) except that amino acids 361-384 are substituted with the amino acid sequence: Gly Ala Ala Asn Leu His Cys Asn Tyr Asn Lys Arg Lys Arg Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Lys Asn Ile Ile Gly Thr Ile Cys Met Gln Gly Pro Ala Asp (SEQ ID NO:8) and amino acid Glu at position 553 is deleted (ntPE-V3MN26).

### Claim 15 (depends on 1)

The immunogen of claim 1 wherein the non-native epitope is an epitope from a viral, bacterial or parasitic protozoan pathogen.

### Claim 16 (depends on 9)

The immunogen of claim 9 wherein the non-native epitope is an epitope of a V3 loop of gp120 of HIV-1.

### Claim 17 (depends on 9)

The immunogen of claim 9 wherein the non-native epitope is an epitope of a principal neutralizing loop of a retrovirus.

### Claim 18 (depends on 9)

The immunogen of claim 9 wherein the non-native epitope is an epitope of a major neutralizing loop of HIV-2 or a V3 loop of gp120 of HIV-1 of at least 8 amino acids including a V3 loop apex.

### Claim 19

A recombinant polynucleotide comprising a nucleotide sequence encoding a non-toxic Pseudomonas exotoxin A-like (“PE-like”) chimeric immunogen, the PE-like chimeric immunogen comprising: (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a translocation domain comprising an amino acid sequence substantially identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol; and (3) a non-native epitope domain comprising an amino acid sequence of between 5 and 1500 amino acids that encodes a non-native epitope.

### Claim 20 (depends on 19)

The recombinant polynucleotide of claim 19 which is an expression vector further comprising an expression control sequence operatively linked to the nucleotide sequence.

### Claim 21 (depends on 19)

The recombinant polynucleotide of claim 19 wherein the nucleotide sequence encodes the amino acid sequence of PE wherein domain Ib of PE further comprises the non-native epitope between two cysteine residues of domain Ib.

### Claim 22

A recombinant non-toxic Pseudomonas exotoxin A-like (“PE-like”) chimeric immunogen cloning platform comprising a nucleotide sequence encoding: (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a translocation domain comprising an amino acid sequence substantially identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol; and (3) a splicing site between the sequence encoding the translocation domain and the sequence encoding the ER retention domain.

### Claim 23 (depends on 22)

The recombinant cloning platform of claim 22 which is an expression vector further comprising an expression control sequence operatively linked to the nucleotide sequence.

### Claim 24

A method of producing antibodies against a non-native epitope, wherein the non-native epitope naturally exists within a cysteine-cysteine loop comprising the step of inoculating an animal with a non-toxic Pseudomonas exotoxin A-like (“PE-like”) chimeric immunogen, the PE-like chimeric immunogen comprising: (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a translocation domain comprising an amino acid sequence substantially identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol; and a (3) a non-native epitope domain comprising a cysteine-cysteine loop that contains within the loop an amino acid sequence of between 5 and 1500 amino acids that encodes a non-native epitope.

### Claim 25 (depends on 24)

The method of claim 24 wherein the cysteine-cysteine loop comprises no more than about 30 amino acids.

### Claim 26 (depends on 24)

The method of claim 24 wherein the non-native epitope is an epitope of the V3 domain of HIV-1.

### Claim at position 27

27-43. (canceled)
